Expression of WT1 protein and correlation with cellular proliferation in glial tumors.

The expression of Wilms' tumor gene WT1 protein was investigated immunohistochemically in 73 glial tumors, including 60 astrocytic tumors, eight oligodendroglial tumors, and five ependymal tumors. WT1 protein was detected in 70 of the 73 glial tumors (95.9%) examined. Almost all glioblastomas, anaplastic astrocytomas, anaplastic ependymomas, and anaplastic oligodendrogliomas expressed high levels of WT1 protein. A significant (p < 0.001) correlation was found between WT1 protein expression and MIB-1 staining index. Histological examination found that WT1 protein was strongly expressed in the anaplastic portions and areas with perivascular proliferation and high cellularity, implying that WT1 gene might be important in glial tumor cell proliferation. WT1 gene is overexpressed in various types of solid tumors and WT1 protein is a target antigen for cancer immunotherapy. This study indicates that many malignant glial tumors are good candidates for cancer immunotherapy targeting WT1 protein and that WT1 protein expression could be used as a proliferation marker in glial tumors.

[1]  J. Hatazawa,et al.  A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. , 2006, Japanese journal of clinical oncology.

[2]  K. Tabuchi,et al.  Expression of the Wilms' tumor gene product WT1 in glioblastomas and medulloblastomas , 2006, Brain Tumor Pathology.

[3]  H. Sugiyama.  Cancer immunotherapy targeting Wilms’ tumor gene WT1 product , 2005, Expert review of vaccines.

[4]  Toshiki Yoshimine,et al.  Overexpression of the Wilms' tumor gene WT1 in primary astrocytic tumors , 2004, Cancer science.

[5]  T. Kyo,et al.  Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A. Schedl,et al.  WT1 and glomerular function. , 2003, Seminars in cell & developmental biology.

[7]  M. Monden,et al.  Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma , 2003, Cancer science.

[8]  Y. Miyoshi,et al.  Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer , 2003, Cancer science.

[9]  D. Cilloni,et al.  Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients , 2002, Leukemia.

[10]  H. Sugiyama.  Cancer Immunotherapy Targeting WT1 Protein , 2002, International journal of hematology.

[11]  Musaffe Tuna,et al.  Downregulation of Wilms' tumor 1 protein inhibits breast cancer proliferation. , 2002, Biochemical and biophysical research communications.

[12]  S. Miyoshi,et al.  Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers , 2002, International journal of cancer.

[13]  Y. Miyoshi,et al.  High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  P. Hall,et al.  Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. , 2002, Histopathology.

[15]  T. Kudoh,et al.  Growth Inhibition of Human Leukemic Cells by WTl ( Wilms Tumor Gene ) Antisense Oligodeoxynucleotides : Implications for the Involvement of WT 1 in Leukemogenesis , 2002 .

[16]  D. Haber,et al.  Wilms tumor and the WT1 gene. , 2001, Experimental cell research.

[17]  H. Sugiyama.  Wilms’ Tumor GeneWT1: Its Oncogenic Function and Clinical Application , 2001, International journal of hematology.

[18]  K. Aozasa,et al.  Cancer Immunotherapy Targeting Wilms’ Tumor Gene WT1 Product1 , 2000, The Journal of Immunology.

[19]  H. Sugiyama,et al.  Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product , 2000, Immunogenetics.

[20]  Y. Oji,et al.  Expression of the Wilms' Tumor Gene WT1 in Solid Tumors and Its Involvement in Tumor Cell Growth , 1999, Japanese journal of cancer research : Gann.

[21]  J. Hata.  Wilms' tumor and the WT1 gene. , 1999, Contributions to nephrology.

[22]  A. Jochemsen,et al.  The Wilms' tumor 1 gene: oncogene or tumor suppressor gene? , 1998, International review of cytology.

[23]  D. Haber,et al.  Functional properties of WT1. , 1996, Medical and pediatric oncology.

[24]  T. Kyo,et al.  Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. , 1996, Blood.

[25]  T. Kudoh,et al.  Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. , 1996, Blood.

[26]  S M Hewitt,et al.  Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. , 1995, Cancer research.

[27]  T. Akiyama,et al.  WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. , 1994, Blood.

[28]  P. Hall,et al.  Detection of the Ki‐67 antigen in fixed and wax‐embedded sections with the monoclonal antibody MIB1 , 1993, Histopathology.

[29]  D. Housman,et al.  Alternative splicing and genomic structure of the Wilms tumor gene WT1. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Poustka,et al.  Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping , 1990, Nature.

[31]  D. Housman,et al.  Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus , 1990, Cell.